0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Letter   |    
The Schizophrenia Algorithm
Leo H. Berman, M.D.
Psychiatric Services 1999; doi:

To the Editor: The article by Dr. John Chiles and his colleagues (1) in the January 1999 issue about the schizophrenia algorithm developed by the Texas Medication Algorithm Project (TMAP) raises a question. Since clozapine is the final drug choice when other drugs fail, why not use it right off the bat?

I suppose one answer might be that the Food and Drug Administration has recommended it only for drug-resistant patients, but is that recommendation binding? Another reason might be the risk of agranulocytosis, but I have used clozapine with many patients, and in only one case did the drug have to be discontinued because of a drop in the white blood cell count. There are so many advantages. Why delay?

The question also arises about using clozapine in new cases of schizophrenia. It has been shown that young, first-break schizophrenic patients have a better prognosis and less danger of developing chronic illness with early treatment. The cost savings by avoiding hospitalization is another reason it might be advantageous to use clozapine as a first-line treatment. I haven't used clozapine for a newly diagnosed schizophrenic patient, but I'm not sure why. Can the authors comment?

Dr. Berman is a psychiatrist in Westport, Connecticut.

Chiles JA, Miller AL, Crismon ML, et al: The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. Psychiatric Services 50:69-74,  1999
 
+

References

Chiles JA, Miller AL, Crismon ML, et al: The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. Psychiatric Services 50:69-74,  1999
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 6.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 10.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles